Trial Profile
An Open-Label, Multi-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability,'BR'Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients with Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Jun 2014
Price :
$35
*
At a glance
- Drugs Omaveloxolone (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- 05 Jun 2014 New trial record